PDCD1 and non-small cell lung carcinoma: For example, encouraging results have been achieved with two antibodies against PD‐1 (nivolumab and pembrolizumab) and PD‐L1 (atezolizumab and durvalumab), which have recently been approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for treating advanced NSCLC.16, 17, 18, 19